首页> 外文期刊>Journal of Medicinal Chemistry >Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective beta-Secretase (BACE1) Inhibitors over BACE2
【24h】

Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective beta-Secretase (BACE1) Inhibitors over BACE2

机译:通过利用明确水分子来改善选择性的基于结构的方法:在Bace2上发现选择性β-分泌酶(Bace1)抑制剂的发现

获取原文
获取原文并翻译 | 示例
           

摘要

BACE1 is an attractive target for disease-modifying treatment of Alzheimer's disease. BACE2, having high homology around the catalytic site, poses a critical challenge to identifying selective BACE1 inhibitors. Recent evidence indicated that BACE2 has various roles in peripheral tissues and the brain, and therefore, the chronic use of nonselective inhibitors may cause side effects derived from BACE2 inhibition. Crystallographic analysis of the nonselective inhibitor verubecestat identified explicit water molecules with different levels of free energy in the S2' pocket. Structure-based design targeting them enabled the identification of propynyl oxazine 3 with improved selectivity. Further optimization efforts led to the discovery of compound 6 with high selectivity. The cocrystal structures of 7, a close analogue of 6, bound to BACE1 and BACE2 confirmed that one of the explicit water molecules is displaced by the propynyl group, suggesting that the difference in the relative water displacement cost may contribute to the improved selectivity.
机译:BACE1是治疗阿尔茨海默病的一个有吸引力的靶点。BACE2在催化位点附近具有高度同源性,对识别选择性BACE1抑制剂提出了严峻挑战。最近的证据表明,BACE2在外周组织和大脑中具有多种作用,因此,长期使用非选择性抑制剂可能会导致BACE2抑制产生的副作用。对非选择性抑制剂verubecestat的晶体学分析表明,S2'口袋中的水分子具有不同水平的自由能。以它们为靶点的基于结构的设计使丙炔基恶嗪3的鉴定具有更好的选择性。进一步的优化工作导致发现了具有高选择性的化合物6。与BACE1和BACE2结合的7的共晶结构(6的紧密类似物)证实了一个显式水分子被丙炔基取代,表明相对水置换成本的差异可能有助于提高选择性。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2021年第6期|共11页
  • 作者单位

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Drug Discovery &

    Dev Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Drug Discovery &

    Dev Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Drug Discovery &

    Dev Toyonaka Osaka 5610825 Japan;

    Shion Pharmaceut Res Ctr Lab Drug Discovery &

    Dis Res Toyonaka Osaka 5610825 Japan;

    Janssen Res &

    Dev Neurosci B-2340 Beerse Belgium;

    Janssen Res &

    Dev Discovery Sci B-2340 Beerse Belgium;

    Janssen Res &

    Dev Discovery Sci B-2340 Beerse Belgium;

    Shion Pharmaceut Res Ctr Lab Med Chem Res Toyonaka Osaka 5610825 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号